200
Participants
Start Date
March 15, 2026
Primary Completion Date
December 15, 2026
Study Completion Date
December 15, 2026
ENA-001
ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
Lead Sponsor
Enalare Therapeutics Inc.
INDUSTRY